SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
  • 2
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
  • 3
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200.
  • 4
    Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127(suppl 1):S268-S276.
  • 5
    Lai Q, Merli M, Ginanni Corradini S, Mennini G, Gentili F, Molinaro A, et al. Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation: a multivariate analysis. Transplant Proc 2009;41:1306-1309.
  • 6
    Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007;245:51-58.
  • 7
    Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int 2007;20:747-753.
  • 8
    Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008;49:581-588.
  • 9
    Hu J, Wang Z, Fan J, Dai Z, He YF, Qiu SJ, et al. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One 2011;6:e26003.
  • 10
    Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 2005;5(pt 1):788-794.
  • 11
    Söderdahl G, Bäckman L, Isoniemi H, Cahlin C, Höckerstedt K, Broomé U, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006;19:288-294.
  • 12
    Pérez Saborido B, Meneu JC, Moreno E, García I, Moreno A, Fundora Y. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg 2005;190:383-387.
  • 13
    Oldhafer KJ, Chavan A, Frühauf NR, Flemming P, Schlitt HJ, Kubicka S, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998;29:953-959.
  • 14
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858.
  • 15
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; for SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
  • 16
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
  • 17
    Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009;7:41.
  • 18
    Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999;67:510-513.
  • 19
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
  • 20
    Morris HP, Slaughter LJ. Historical development of transplantable hepatomas. Adv Exp Med Biol 1977;92:1-19.
  • 21
    Kamada N, Calne RY. A surgical experience with five hundred thirty liver transplants in the rat. Surgery 1983;93(pt 1):64-69.
  • 22
    Gao W, Lemasters JJ, Thurman RG. Development of a new method for hepatic rearterialization in rat orthotopic liver transplantation. Reduction of liver injury and improvement of surgical outcome by arterialization. Transplantation 1993;56:19-24.
  • 23
    Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49:491-503.
  • 24
    Matsuzaki T, Murase N, Yagihashi A, Shinozuka H, Shimizu Y, Furuya T, et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. Transplant Proc 1992;24:748-751.
  • 25
    Ceriello A, Mezza F, Cozzolino S, Pettinato G, Mancini A, Santaniello W, et al. Role of immunosuppression in recurrence after liver transplantation for diethylnitrosamine-induced tumors in rats. Transpl Int 1994;7(suppl 1):S204-S207.
  • 26
    Kamada N. The immunology of experimental liver transplantation in the rat. Immunology 1985;55:369-389.
  • 27
    Li X, Zheng CS, Feng GS, Zhuo CK, Zhao JG, Liu X. An implantable rat liver tumor model for experimental transarterial chemoembolization therapy and its imaging features. World J Gastroenterol 2002;8:1035-1039.
  • 28
    Qian J, Truebenbach J, Graepler F, Pereira P, Huppert P, Eul T, et al. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J Gastroenterol 2003;9:94-98.
  • 29
    Slooter GD, Marquet RL, Jeekel J, Ijzermans JN. Tumour growth stimulation after partial hepatectomy can be reduced by treatment with tumour necrosis factor alpha. Br J Surg 1995;82:129-132.
  • 30
    de Jong KP, Lont HE, Bijma AM, Brouwers MA, de Vries EG, van Veen ML, et al. The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology 1995;22(pt 1):1263-1272.
  • 31
    Justinger C, Schlüter C, Oliviera-Frick V, Kopp B, Rubie C, Schilling MK. Increased growth factor expression after hepatic and pancreatic resection. Oncol Rep 2008;20:1527-1531.
  • 32
    Tamagawa K, Horiuchi T, Uchinami M, Doi K, Yoshida M, Nakamura T, et al. Hepatic ischemia-reperfusion increases vascular endothelial growth factor and cancer growth in rats. J Surg Res 2008;148:158-163.
  • 33
    Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991;68:2095-2100.
  • 34
    Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009;115:4646.